Liquidia (LQDA) Income from Continuing Operations (2020 - 2026)
Liquidia (LQDA) posted quarterly Income from Continuing Operations of 52882000.0 for Q1 2026, up 237.83% year-over-year from 15653342.91 in Q1 2025, and up 263.33% quarter-over-quarter from 14555000.0 in Q4 2025.
Liquidia (LQDA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Liquidia's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 52882000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 237.83% year-over-year to 52882000.0; the TTM figure through Mar 2026 stood at 186865000.0 (up 23.86% YoY), while the FY2025 annual figure was 293685000.0, down 28.44% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 52882000.0, up from 14555000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 52882000.0 in Q1 2026, with the low at 149910000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 31183000.0 (2023), against an average of 44210647.06.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations sank 435.09% in 2023, then soared 237.83% in 2026.
- Liquidia's Income from Continuing Operations stood at 5130000.0 in 2022, then tumbled by 435.09% to 27450000.0 in 2023, then slumped by 40.29% to 38510000.0 in 2024, then soared by 137.8% to 14555000.0 in 2025, then surged by 263.33% to 52882000.0 in 2026.
- Business Quant data shows LQDA's Income from Continuing Operations at 52882000.0 in Q1 2026, 14555000.0 in Q4 2025, and 149910000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Liquidia | 6.52 Bn | 6.23 Bn | 160.92 Mn | 74.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.70 Mn |
| Mar 31, 2026 | 52.88 Mn |
| Dec 31, 2025 | 14.56 Mn |
| Sep 30, 2025 | -149.91 Mn |
| Jun 30, 2025 | -104.39 Mn |
| Mar 31, 2025 | -38.37 Mn |
| Dec 31, 2024 | -38.51 Mn |
| Sep 30, 2024 | -75.21 Mn |
| Jun 30, 2024 | -93.32 Mn |
| Mar 31, 2024 | -121.96 Mn |
| Dec 31, 2023 | -27.45 Mn |
| Sep 30, 2023 | -31.18 Mn |
| Jun 30, 2023 | -53.03 Mn |
| Mar 31, 2023 | -31.00 Mn |
| Dec 31, 2022 | -5.13 Mn |
| Sep 30, 2022 | -19.38 Mn |
| Jun 30, 2022 | -14.35 Mn |
| Mar 31, 2022 | -15.82 Mn |
| Dec 31, 2021 | -11.47 Mn |
| Sep 30, 2021 | -13.74 Mn |